When Bad Data Enters the Drug Pipeline - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

  • By

  • Kathryn Wighton

  • June 11, 2026

  • 2 min

Share

  • 1

    Jaynier Moya, MD, and three coordinators face charges for allegedly falsifying data in drug trials at Pines Care Research Center.

  • 2

    The alleged misconduct reportedly began no later than 2019, involving false records of participant medication and testing.

  • 3

    Prosecutors claim identification documents from non-participants were used to create fraudulent participant records.

  • 4

    Falsified data was allegedly submitted into clinical trial databases, impacting evaluations of new drugs.

  • 5

    The case highlights the importance of data integrity in clinical trials for regulatory evaluations and public confidence.

Original Source(s)

When Bad Data Enters the Drug Pipeline

  • by Kathryn Wighton

  • June 11, 2026

Related Content

FDA approves hepcidin mimetic for PV

Phase 3 VERIFY results showed a 77% clinical response rate during weeks 20 to 32.

Medical Oddities: Dogs share our mortality markers

The bond with dogs runs deeper, the brain enjoys a good sweat, love on screen gets real, and tea carries a little more weight.

FDA expands essential thrombocythemia care

Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.